Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080291 | 0.88 | CTSK (0.44) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL12321230 | 0.87 | CTSK (0.59) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL3942865 | 0.87 | CTSK (0.59) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL3544236 | 0.87 | CTSK (0.59) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL24690240 | 0.87 | CTSK (0.48) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL31048087 | 0.87 | CTSK (0.43) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL25085760 | 0.87 | CTSK (0.43) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL13016625 | 0.85 | CTSK (0.42) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL342772 | 0.85 | CA1 (0.62) | CTSKCA1CA2BTKCYP2C9 | |
| SCHEMBL342773 | 0.85 | CA1 (0.62) | CTSKCA1CA2BTKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3050885-B1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170145021-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC | 2017-05-25 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-3050885-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | Glaxosmithkline LLC (US) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145021-A1 | NOVEL COMPOUNDS | GABRE, GABRA1, GABRA6 | CTSK 3402/4885CA1 1315/4885CA2 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.